Oncozenge AB (ONCOZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncozenge AB (ONCOZ) has a cash flow conversion efficiency ratio of 12.336x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.24 Million ≈ $-779.25K USD) by net assets (Skr-587.00K ≈ $-63.17K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Oncozenge AB for the company's overall valuation and market capitalisation.
Oncozenge AB - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Oncozenge AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oncozenge AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncozenge AB ranked by their cash flow conversion efficiency. Explore Oncozenge AB cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FRESH FACTORY B.C.
F:Q4Z
|
-0.080x |
|
SATO Technologies Corp
V:SATO
|
-0.336x |
|
Green Ocean Corporation Bhd
KLSE:0074
|
0.002x |
|
Llama Group S.A.
PA:ALLAM
|
0.411x |
|
North Stawell Minerals Ltd
AU:NSM
|
-0.045x |
|
Technoplus Ventures Ltd
TA:TNPV
|
-0.040x |
|
Bullfrog AI Holdings, Inc. Common Stock
NASDAQ:BFRG
|
-0.570x |
|
UNIDOC HEALTH CORP.
F:L7T
|
41.739x |
Annual Cash Flow Conversion Efficiency for Oncozenge AB (2020–2025)
The table below shows the annual cash flow conversion efficiency of Oncozenge AB from 2020 to 2025. View ONCOZ stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-587.00K ≈ $-63.17K |
Skr-13.06 Million ≈ $-1.41 Million |
22.244x | +2625.38% |
| 2024-12-31 | Skr9.95 Million ≈ $1.07 Million |
Skr-8.76 Million ≈ $-943.15K |
-0.881x | +3.89% |
| 2023-12-31 | Skr18.64 Million ≈ $2.01 Million |
Skr-17.08 Million ≈ $-1.84 Million |
-0.916x | -41.02% |
| 2022-12-31 | Skr33.97 Million ≈ $3.66 Million |
Skr-22.08 Million ≈ $-2.38 Million |
-0.650x | -995.02% |
| 2021-12-31 | Skr80.32 Million ≈ $8.64 Million |
Skr-4.77 Million ≈ $-513.01K |
-0.059x | -173676.54% |
| 2020-12-31 | Skr29.28 Million ≈ $3.15 Million |
Skr-1.00K ≈ $-107.62 |
0.000x | -- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.